X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Featured

AAV Gene Therapy CDMOs Shaping The Future With A $2.57B Goal

Content Team by Content Team
31st August 2023
in Featured, Manufacturing, Trends

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The global market for cell and gene therapy biomanufacturing Contract Development and Manufacturing Organizations (CDMOs), with a specific focus on Adeno-Associated Virus (AAV), witnessed remarkable growth, valued at $0.2313 billion in 2022. Projections indicate that by 2033, this market is set to reach an impressive $2.566 billion, experiencing a noteworthy Compound Annual Growth Rate (CAGR) of 24.61% over the forecast period from 2023 to 2033.

This expansion is primarily attributed to the escalating clinical activities tied to viral-vector based gene therapies, coupled with substantial investments made by CDMOs to enhance viral-vector manufacturing and gene therapy research.

The global cell and gene therapy biomanufacturing CDMO market, with its spotlight on AAV, is currently in a progressive stage. AAV-based gene therapies have garnered substantial attention due to their potential in addressing diverse genetic disorders and diseases. Collaborations between therapy developers and CDMOs are pivotal in expediting the availability of cutting-edge AAV-based therapies. By outsourcing manufacturing to CDMOs, developers can concentrate on research and clinical activities, thereby accelerating production and time-to-market for these therapies. Considerable investments in research and development further propel advancements in the field.

Nevertheless, challenges encompass maintaining scalability and stringent quality control standards amid the increasing demand for AAV-based therapies. Intensifying competition could lead to price pressures, potentially impacting the profit margins of CDMOs.

The growth trajectory of the global cell and gene therapy biomanufacturing CDMO market, with a focus on AAV, hinges on factors such as rising clinical activities, amplified demand for AAV-specialized CDMOs, and collaborations between therapy developers and CDMOs. These collaborations can expedite the commercialization of AAV-based therapies, benefiting both parties. The entry of new players might intensify competition, resulting in price pressures. Technological advancements in AAV biomanufacturing could streamline processes, offering CDMOs that adopt these innovations a competitive edge.

The COVID-19 pandemic introduced disruptions to the cell and gene therapy biomanufacturing CDMO market, affecting operations, manufacturing timelines, and clinical trials. Economic uncertainties influenced funding and investment decisions, potentially impeding CDMO expansion and technological progress. Regulatory processes also encountered delays and modifications. However, as the situation stabilizes, the industry is expected to recover and drive advancements in AAV-based therapies.

The market is segmented based on development phases, workflows, indications, culture types, and regions. Drivers include increased activities in viral-vector-based gene therapies, emerging players in the sector, and significant CDMO investments. Restraints involve limitations in large-scale AAV biomanufacturing methods and high manufacturing costs for emerging CDMOs. Opportunities arise from collaborative AAV biomanufacturing facility development.

Key market players contributing to the evolution of the cell and gene therapy biomanufacturing CDMO market, with an emphasis on AAV, include AGC Biologics, Charles River Laboratories, Catalent, Danaher (Cytiva), Lonza, Merck KGaA, among others. As the market evolves, CDMOs must invest in technologies and compliance to meet the burgeoning demand for AAV therapies. This high demand fuels growth and global expansion opportunities for CDMOs while transforming patient care.

Previous Post

Temperature Management For Pharmaceutical Logistics Success

Next Post

Rising Demand For CDMOs Amid COVID-19 Reshaping API Market

Related Posts

FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Insights

Smart Drug Delivery Systems for Patient Care

27th September 2025
Insights

Green Chemistry in Sustainable API Manufacturing

26th September 2025
active pharmaceutical ingredients supply chain
Drug Development

Future of Active Pharmaceutical Ingredients Supply

26th September 2025
Next Post

Rising Demand For CDMOs Amid COVID-19 Reshaping API Market

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In